Sign in

    Daniel Tassé

    Chief Executive Officer at Dbv Technologies SA
    Board
    Since November 2018
    Age
    64 years
    Education
    Earned a Bachelor of Science (B.Sc.) in Biochemistry from Université de Montréal.
    Tenure
    Joined DBVT as Chief Executive Officer in November 2018 and became a board member in March 2019.

    Also at Dbv Technologies SA

    DPM
    Dr. Pharis Mohideen
    Chief Medical Officer
    VB
    Virginie Boucinha
    Chief Financial Officer

    About

    Daniel Tassé is a seasoned executive with extensive experience in the biotechnology and pharmaceutical sectors, currently serving as the Chief Executive Officer at DBVT since November 2018.

    With a strong educational background that includes a Bachelor of Science in Biochemistry from Université de Montréal, he has built a career marked by strategic leadership and a commitment to advancing clinical programs.

    Beyond his role at DBVT, he has held various leadership positions and board memberships at several notable companies, reflecting a robust track record in corporate governance and operational excellence.

    $DBVT Performance Under Daniel Tassé

    Past Roles

    OrganizationRoleDate RangeDetails
    Indivior plc Board Director (Lead Independent Director, Interim Chair, Audit Committee Chair) 2013 – 2021 N/A
    HLS Therapeutics Board of Directors 2018 – 2019 N/A
    Bellerophon Therapeutics, Inc. Board of Directors 2014 – 2019 N/A
    Alcresta Therapeutics, Inc. Chairman & Chief Executive Officer Mar 2016 – Nov 2018 N/A
    Ikaria, Inc. Chairman & Chief Executive Officer Jan 2008 – Apr 2015 Acquired by Mallinckrodt Pharmaceuticals in Apr 2015

    External Roles

    OrganizationRoleDate RangeDetails
    Autous Independent Director Appointed April 2024 Nasdaq-listed company
    Regenxbio Inc. Board Director & Compensation Committee Chair Since 2016 N/A

    Fixed Compensation

    Data from  FY 2023
    Component NameAmountPayment ScheduleAdditional Details
    Base Salary $600,000 Annual Fixed compensation for the CEO
    Option Awards $1,084,783 At grant dateAggregate grant date fair value computed in accordance with ASC Topic 718
    Non-Equity Incentive Plan Compensation $600,000 Contingent on performance (achieved 106% of objectives, approved Jan 16, 2024) Converted from euros using the BCE exchange rate
    All Other Compensation $119,703 As applicableIncludes benefit plan contributions ($50,750 ), life insurance premiums ($37,457 ), tax gross-up payments ($30,512 ), and commuting expenses ($984 )

    Performance Compensation

    Data from  FY 2023

    Performance Compensation

    Performance Metrics and Targets

    MetricBase PointsAdditional PointsTotal Points
    Viaskin Peanut – VITESSE clinical study progress 64 33 97
    Viaskin Peanut – BLA file preparation 64 33 97
    Pipeline Development – Mag1c program 21 7 28
    Pipeline Development – Ongoing preclinical/clinical studies 21 7 28
    Quarterly Cash Burn Targets 15 8 23
    Operating Targets 15 8 23

    Total Base Points: 100
    Total Additional Points: 48

    Achievement

    Achieved 106% of the performance criteria (determined by the Board on January 16, 2024).

    Stock Option Grant (Performance-Linked)

    • Grant Date: November 20, 2023
    • Number of Options: 809,672
    • Exercise Price: €2.00
    • Vesting Schedule: 4-year staggered vesting; 25% vesting each anniversary; options exercisable until November 20, 2033
    • Grant Date Fair Value: €1,631,372

    Additional Performance Component

    • Tax Equalization Payment: $28,522

    Severance Conditions (Performance Related)

    • Viaskin Peanut approval in a major market
    • EPIT pipeline with three ongoing clinical trials
    • Six months cash runway as of termination date